Hostile Interpretation Bias Training to Treat Irritability
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03592368 |
Recruitment Status :
Recruiting
First Posted : July 19, 2018
Last Update Posted : November 14, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Irritable Mood Mood Disorders | Device: IBT | Not Applicable |
This trial lays the foundation for a preliminary test of efficacy of IBT on irritability by establishing IBT's neurocognitive treatment targets: hostile interpretation bias and response in the neural threat-learning system.
The design is a single-blinded, randomized controlled trial of IBT on its targets. The study will have four arms, with 25 participants in each arm for all four conditions of training (active versus sham) and scanning (in MRI or out of MRI scanner). During IBT, participants judge as happy or angry facial expressions which are on a continuum between happy and angry. The point at which judgments shift from predominantly happy to angry on this continuum is the indifference point. During training feedback encourages no change in the indifference point or a change in the indifference point towards more happy judgments of ambiguous faces. A shift in indifference point towards more benign judgments is interpreted as a reduction in hostile interpretation.
The design will test whether active relative to sham IBT shifts the indifference point towards more benign judgments. Neural response to active versus sham IBT will be measured in half the sample.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 100 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single (Participant) |
Primary Purpose: | Basic Science |
Official Title: | Neurocognitive Targets of Hostile Interpretation Bias Training to Treat Irritability |
Actual Study Start Date : | October 15, 2018 |
Estimated Primary Completion Date : | February 2023 |
Estimated Study Completion Date : | February 2023 |
Arm | Intervention/treatment |
---|---|
Active Comparator: Active IBT, Out of MRI |
Device: IBT
Interpretation bias training |
Sham Comparator: Sham IBT, Out of MRI |
Device: IBT
Interpretation bias training |
Active Comparator: Active IBT, In MRI |
Device: IBT
Interpretation bias training |
Sham Comparator: Sham IBT, In MRI |
Device: IBT
Interpretation bias training |
- Change in Interpretation Bias [ Time Frame: Up to one day before and after the single 1 day training session of Interpretation bias training session. ]Interpretation bias is measured by the indifference point of happy-angry judgments of a continuum of morphed images between happy=1 to angry=15 facial expressions. Lower indifference points indicate a higher bias towards hostile (or angry) judgments. Change in interpretation bias is the difference between the post- and pre-IBT indifference points.
- Neural response in threat learning system. [ Time Frame: During the course of the 1 day single session of interpretation bias training session. ]Amygdala functional connectivity to ventromedial prefrontal cortex is measured by covariance in fluctuations in blood oxygen-level dependent signal between these regions during functional magnetic resonance imaging during the course of training. These fluctuations are expected to be significantly modulated by interpretation bias training.
- Learning Rate [ Time Frame: During the course of the 1 day single interpretation bias training session. ]Learning rate as measured by a reinforcement learning computational model during IBT. It measures the average trial-by-trial change in happy or angry judgments in response to feedback during a session of IBT.
- Irritability [ Time Frame: Within one week prior to Interpretation bias training and one week +/- 3 days after Interpretation bias training. ]Tendency towards anger and temper outburst as measured by the Affective Reactivity Index.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 13 Years to 17 Years (Child) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
-
Adolescents in mental health treatment, with at least:
- mild, clinically significant irritability, and
- typical intellectual functioning (IQ>80)
Exclusion Criteria:
-
Any of the following mental health diagnoses:
- current post-traumatic stress
- lifetime bipolar I or II disorder
- lifetime cyclothymic disorder
- lifetime psychotic disorder
- lifetime autism spectrum disorder
- Major medical problems, including head trauma.
- MRI-specific safety exclusions for the MRI arms.
- Clinical instability.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03592368
Contact: Joel Stoddard, MD | 720-777-5702 | joel.stoddard@ucdenver.edu |
United States, Colorado | |
University of Colorado, School of Medicine | Recruiting |
Aurora, Colorado, United States, 80045 | |
Contact: Joel Stoddard, MD 720-777-5702 joel.stoddard@ucdenver.edu |
Principal Investigator: | Joel Stoddard, MD | University of Colorado, Denver |
Responsible Party: | University of Colorado, Denver |
ClinicalTrials.gov Identifier: | NCT03592368 |
Other Study ID Numbers: |
17-0464 |
First Posted: | July 19, 2018 Key Record Dates |
Last Update Posted: | November 14, 2022 |
Last Verified: | November 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Plan Description: | A commitment to data sharing and analytic code has been made. Specifics of the data sharing plan require further work due to the collection of protected health information. |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | Yes |
Device Product Not Approved or Cleared by U.S. FDA: | Yes |
Product Manufactured in and Exported from the U.S.: | No |
Mood Disorders Mental Disorders |